Don’t Just Lose Weight. Know What You’re Losing.
You stepped on the scale. It says you have lost 30 pounds. That is worth celebrating—but the scale cannot tell you what those 30 pounds were.
Maybe you lost mostly body fat. Maybe you lost more lean tissue than you realize. The number on your scale does not know the difference.
Significant weight loss with semaglutide can include a reduction in lean mass. But lean mass is not the same as skeletal muscle, and the amount you preserve is strongly influenced by protein intake, resistance training, dose progression, hydration and the speed of weight loss.
The better question is: How much fat did I lose, how much muscle and strength did I preserve, and can I maintain the result?
26 lb fat + 4 lb lean tissue
A highly favorable body-composition result.
18 lb fat + 12 lb lean tissue
The same scale result—but a very different clinical outcome.
Why “muscle loss” is the wrong question
Weight is a container word. What comes off during weight loss is always a mixture: fat, water, stored glycogen, connective tissue, some organ mass, and some skeletal muscle. Every weight loss method ever studied — dieting, bariatric surgery, exercise, medication — takes some of each. No intervention removes fat and nothing else. That isn’t a limitation of GLP-1 drugs. It’s a limitation of bodies.
So “does this medication cause muscle loss” isn’t the useful question. The useful question is: of the weight I lose, what share is fat, what share isn’t, and is that trade acceptable for me?
That reframe matters because it puts the conversation somewhere you have leverage. You can’t opt out of losing some lean tissue. You can absolutely change the ratio.
The actual numbers: semaglutide, tirzepatide, retatrutide
Three medications, three different bodies of evidence. Here is what the DEXA data from the major trials reported.
STEP 1 average body-weight change at 68 weeks; its small DEXA substudy also reported substantial fat and visceral-fat reduction.
SURMOUNT-1 DEXA substudy: approximately 75% of the lost weight was fat mass and about 25% was lean mass.
TRIUMPH-1 Phase 3 efficacy-estimand result at 80 weeks—but without a detailed Phase 3 DEXA breakdown.
| Medication | Trial & duration | Body weight | Fat mass | Lean mass | Share of loss that was lean |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy®) |
STEP 1 DEXA substudy 68 weeks, n=140 |
−15.0% | −19.3% visceral fat −27.4% |
−9.7% | ~40–45% (analyses disagree) |
| Tirzepatide (Zepbound®) |
SURMOUNT-1 DEXA substudy 72 weeks, n=160 |
−21.3% | −33.9% | −10.9% | ~25% |
| Retatrutide investigational — not FDA-approved |
Phase 2 body composition substudy (type 2 diabetes) 36 weeks, n=189 |
up to −16.9% | up to −26.1% | — | ~35% |
Figures as reported in the published trial substudies. Populations, durations, scanners, and analytic methods differ between trials — see the section below on why these numbers cannot be read as a head-to-head comparison. Note that retatrutide’s figures come from a phase 2 substudy in people with type 2 diabetes; no detailed body-composition data has been released from any phase 3 retatrutide trial, despite the much larger weight loss those trials produced.
Read the last column, then read it again. Tirzepatide produced meaningfully more total weight loss than semaglutide, and yet a smaller proportion of that loss was lean tissue. That’s the finding everyone quotes.
And it’s where I have to be honest with you, because that comparison is nowhere near as clean as the internet presents it.
Ten things GLP-1 muscle-loss studies do not tell you
Trials lead with body weight
The headline usually reports total weight loss—not how much came from fat, lean tissue or water.
Lean mass is not muscle
DEXA lean mass includes skeletal muscle, water, glycogen, organs, connective tissue and other nonfat tissue.
DEXA does not directly measure muscle
It estimates compartments and cannot prove that every pound of lost lean mass was contractile muscle.
The same trial can produce different numbers
Different calculations and assumptions can produce different estimates from the same study population.
Most participants were not on a true preservation program
Structured resistance training, individualized protein targets and body-composition feedback were usually limited.
There is no clean head-to-head muscle trial
Semaglutide and tirzepatide body-composition figures come from different studies, scanners and methods.
Relative composition may improve
Absolute lean mass can fall while lean mass becomes a larger percentage of the smaller body.
Strength may remain stable—or improve
Function and performance often tell you more than a single lean-mass number on a scan.
Bone loss deserves more attention
Bone mineral density can decline during major weight loss, especially in older adults and higher-risk patients.
More weight loss raises the stakes
Retatrutide-level weight loss increases the absolute amount of lean tissue at stake, even when the percentage looks similar.
In TRIUMPH-1, participants receiving retatrutide 12 mg lost an average of 70.3 pounds, and 45.3% lost at least 30% of their starting weight.
But the Phase 3 topline release did not tell us how much of those 70.3 pounds was fat, skeletal muscle, water or other lean tissue.
Want your own numbers instead of a statistic from someone else’s trial?
Book a ConsultationThe four questions every GLP-1 patient should ask
How to actually track it
DEXA — the reference standard, with an asterisk
DEXA remains the most reliable widely available option, and it gives you something the others don’t: bone mineral density, which as noted above may be the more important number. Scan before you start if you can, then every three to six months, always on the same machine. Comparing scans between different machines introduces error larger than the change you’re trying to detect.
The asterisk is everything in point 2 above: DEXA measures lean soft tissue, not muscle. Interpret the trend, not the decimal.
Smart scales and body composition devices
Home devices like the Hume Body Pod and Withings Body Scan, and in-office analyzers like InBody, all use bioelectrical impedance analysis. BIA sends a small current through the body, estimates total body water from the resistance it encounters, and derives fat-free mass from an assumption about how much of lean tissue is water.
On a GLP-1, that assumption is unusually fragile — and this is a practical trap I see constantly:
The dehydration trap
You’re eating less, which means less water from food. You may be nauseated. You may be losing fluid to GI side effects. All of that lowers your body water.
Lower body water means higher electrical resistance. The BIA algorithm interprets higher resistance as more fat and less lean tissue. Studies have found hydration shifts can swing lean mass estimates by 5–10% in acute phases.
Translation: a dehydrated scale reading will tell you you’re losing muscle when what you’ve actually lost is water. Then you panic, and you make a decision based on a measurement error.
A single smart-scale reading should never drive a dose change, a panic increase in calories or the conclusion that muscle has suddenly disappeared. I care more about the trend under standardized conditions, waist change and whether strength is stable over eight to twelve weeks.
These devices are still useful — for trend, under controlled conditions. Weigh first thing in the morning, after using the bathroom, before eating or drinking, same day of the week. Never compare a morning reading to an evening one. And never let a single reading change your plan.
The two metrics I trust most are free
What you can lift, and for how many reps. Strength on the same handful of movements, compared eight to twelve weeks apart, tracks functional contractile muscle better than any consumer device on the market. If your squat, your row, and your press are holding steady or climbing while the scale falls, you are doing this correctly — regardless of what a bathroom device tells you.
Waist circumference. Cheap, reproducible, and it tracks the visceral fat that actually drives cardiometabolic risk. Same spot, same time of day, tape snug but not compressing.
Progress photos and how clothing fits round it out. If you want the full framework on interpreting body fat percentage itself, I’ve written about that in the number that determines whether you see your abs.
The prevention protocol
Six things, in rough order of how much they matter.
1. Resistance training, 2–3 times per week
This is the non-negotiable one, and nothing else on this list substitutes for it. Progressive overload on compound movements — squat, hinge, push, pull, carry. Resistance training provides the mechanical signal that tells your body keep this tissue, we’re using it. Protein without that signal is building material with no construction order.
You don’t need a bodybuilding program. Two well-structured 40-minute sessions a week, done consistently for a year, will outperform an ambitious five-day plan abandoned in March.
2. Protein: approximately 0.7–1.0 gram per pound of goal body weight per day
For many adults using a GLP-1, a practical target is approximately 0.7–1.0 gram of protein per pound of goal body weight per day. For example, a goal weight of 160 pounds corresponds to roughly 110–160 grams daily; a goal weight of 180 pounds corresponds to roughly 125–180 grams. Distribute protein across three or four meals at about 25–40 grams each rather than loading it all into dinner. Eating the protein portion first can help when appetite is limited.
Here’s the part that makes this hard: one published cohort found that only about 43% of GLP-1 users hit even the minimum 1.2 g/kg target. Appetite suppression means protein is the first thing to quietly disappear from the plate. So: eat the protein first at every meal, before anything else touches the fork. Greek yogurt, cottage cheese, eggs, fish, lean poultry — and a shake on the days when solid food is unappealing.
If you have kidney disease, your protein target needs to be set individually. Talk to your physician before increasing it.
3. Don’t lose it faster than you need to
Roughly one to two pounds per week — or under about 1% of body weight weekly — is the range where the fat-to-lean ratio stays favorable. Aggressive dose escalation produces a more dramatic before-and-after photo at twelve weeks and a worse body composition at twelve months.
The manufacturers’ own data supports this. In TRIUMPH-1, retatrutide’s lowest studied dose delivered 19% weight loss with a discontinuation rate below placebo, while the highest dose bought roughly nine additional percentage points at nearly triple the dropout. More drug is not automatically more benefit, and the top of the dose range is not a target you’re supposed to reach.
Titration is a tool, not a race. If you’re losing faster than that consistently, that’s a conversation with your prescriber, not a win.
4. Hydration
A practical target for many adults is approximately 1 gallon of fluids daily. Hydration supports metabolism, muscle function, exercise performance, recovery, kidney health, and healthy body composition. Increase intake during exercise, hot weather, or if you experience vomiting or diarrhea while taking GLP-1 medications. Individual needs vary based on body size, activity level, climate, kidney and heart health, and other medical conditions. Reduced food intake means reduced water intake from food, and most patients don’t consciously replace it. Dehydration worsens constipation, fatigue, and headaches — and, as covered above, corrupts your body composition readings.
5. Don’t under-eat total calories
A deliberate crash deficit stacked on top of a drug that already suppresses appetite is precisely where lean mass loss stops being adaptive and starts being a problem. The medication is already creating the deficit. You don’t need to add to it.
6. Get a baseline before your first dose
Body composition, relevant labs, waist measurement, and a note of what you can currently lift. If you don’t have a starting number, you have no way of knowing what changed — and no way of catching a problem early enough to correct it.
Board-Certified in Internal Medicine & Obesity Medicine
What’s coming: drugs built to protect muscle
The field has already moved on from arguing about this. Medications designed specifically to preserve lean mass during GLP-1 weight loss are in active trials.
In the phase 2 BELIEVE trial, published in Nature Medicine in 2026, combining bimagrumab — an antibody that blocks activin type II receptors — with semaglutide 2.4 mg produced 22.1% weight loss at 72 weeks, with roughly 92% of that loss coming from fat. Lean mass loss was limited to 2.9%, compared with 7.4% for semaglutide alone. Bimagrumab by itself increased lean mass by 2.5%.
In Regeneron’s phase 2 COURAGE trial — co-led from here in Dallas at UT Southwestern — adding trevogrumab, an anti-myostatin antibody, to semaglutide prevented approximately half of the semaglutide-associated lean mass loss at 26 weeks.
Neither is FDA-approved. Neither is available. But both point the same direction: the question is shifting from how much weight to what kind of weight.
A note on retatrutide
Retatrutide’s phase 3 results are extraordinary: 28.3% average weight loss at 80 weeks in TRIUMPH-1, up to 30.3% at 104 weeks in participants who started with a BMI of 35 or higher, and 28.7% at 68 weeks in TRIUMPH-4. Those figures are why you’re hearing the name.
It is also not FDA-approved. As of mid-2026 it remains investigational, with additional TRIUMPH readouts pending and no completed FDA submission. It cannot legally be prescribed or dispensed as an approved medicine in the United States, and no body composition data from any phase 3 retatrutide trial has been published yet.
So if someone is selling you something labeled retatrutide today, understand what that means: it is not an approved medication, its contents have not been verified by anyone, and nobody — including the manufacturer — has published what it does to your lean mass at 30% weight loss. I’d weigh that carefully.
Where Emsculpt NEO fits — honestly
Nearly every med spa in Dallas will tell you that Emsculpt NEO® prevents muscle loss on a GLP-1. Here is the accurate version.
Emsculpt NEO is FDA-cleared, and in the area it treats, it does build muscle. Published clinical studies and systematic reviews report muscle increases on the order of 20–25% and fat reduction around 25–30% in the treated area. That’s real, it’s measurable, and it’s useful.
EMSCULPT NEO is best viewed as a valuable addition to a comprehensive body-composition plan. It can strengthen and condition the specific muscle groups being treated—such as the abdomen, glutes or arms—and may complement adequate protein intake, resistance training and physician-guided GLP-1 therapy. It is not a replacement for whole-body strength training, and a published randomized trial has not yet established that it prevents total-body lean-mass loss during GLP-1 treatment. Used in the right patient, it can be a meaningful tool for improving regional muscle tone, strength and body contour while the broader program protects overall muscle health.
Where it genuinely earns its place: as a regional finisher for patients who are already handling the protein and the training and want definition in a specific area, or as a bridge for patients who physically can’t resistance train yet — post-injury, deconditioned, or dealing with joint limitations that make loaded movement painful at their current weight. That’s the honest indication, and it’s how we use it here.
Where Sanjiva fits
The reason I wrote all of this is that the GLP-1 market has become extraordinarily good at dispensing medication and extraordinarily bad at everything around it. A subscription and a syringe is not a weight management program. It’s a delivery service.
At Sanjiva Medical Spa in Dallas, medical weight management is run by a physician board-certified in Obesity Medicine — the same physician, every visit. That means a body composition baseline before you start, protein and training targets set for your body rather than copied off a website, titration paced to protect lean mass rather than to produce a fast headline, and monitoring for the things that don’t make the internet’s list, like bone density in patients over 60.
We work with patients across Highland Park, University Park, Preston Hollow, and the Park Cities. Whether the right answer for you is a GLP-1, a different approach entirely, or a conversation about whether now is the right time at all — that’s what a consultation is for.
Frequently asked questions
Does Ozempic cause muscle loss?
Some lean mass loss accompanies any significant weight loss, regardless of method. In the STEP 1 DEXA substudy of semaglutide 2.4 mg, lean mass fell 9.7% while fat mass fell 19.3% over 68 weeks. However, “lean mass” on a DEXA scan includes water, glycogen, connective tissue, and organs alongside skeletal muscle, so the actual contractile muscle loss is smaller than the headline figure suggests. Adequate protein and resistance training substantially change the ratio. Note that Ozempic® is FDA-approved for type 2 diabetes; its use for weight loss is off-label.
How much muscle do you lose on a GLP-1?
Published trials report lean mass accounting for roughly 25–40% of total weight lost, depending on the drug, the trial, and the analysis. That range is comparable to what occurs with diet-only weight loss and bariatric surgery. Because total weight loss is larger with these medications, the absolute pounds of lean tissue lost are larger even when the percentage is similar.
Which is better for preserving muscle, semaglutide or tirzepatide?
The trial substudies suggest tirzepatide loses a smaller proportion of weight as lean mass (~25% versus ~40%), but these figures come from separate trials with different populations and methods — there has never been a head-to-head body composition trial. A 2026 real-world analysis actually found greater lean mass decline with tirzepatide. The evidence does not currently support a confident answer.
How much protein should I eat on a GLP-1?
A practical target for many adults is approximately 0.7–1.0 gram of protein per pound of goal body weight per day, divided across three or four meals at roughly 25–40 grams each. Protein needs should be individualized for age, training, appetite, kidney function and medical history; patients with kidney disease should set their target with their physician.
Are smart scales accurate for tracking muscle on a GLP-1?
They are useful for trends but unreliable for absolute values, because bioelectrical impedance depends on hydration status — which is exactly what fluctuates most on these medications. Dehydration causes these devices to overestimate body fat and underestimate lean mass. Measure at the same time of day under the same conditions, and never change your plan based on a single reading.
Can Emsculpt NEO prevent muscle loss while I’m on a GLP-1?
Emsculpt NEO is FDA-cleared and builds muscle in the area treated, with published studies showing muscle increases around 20–25% in that region. However, no randomized trial has demonstrated that it prevents total-body lean mass loss during GLP-1 therapy. It works best as a targeted addition to adequate protein and resistance training, not as a replacement for either.
Is retatrutide available for weight loss?
No. Retatrutide is an investigational medication in Eli Lilly’s phase 3 TRIUMPH program and is not FDA-approved for any indication as of mid-2026. It cannot legally be prescribed or dispensed as an approved medicine in the United States. Its phase 3 results are striking — 28.3% average weight loss at 80 weeks in TRIUMPH-1, up to 30.3% at 104 weeks in higher-BMI participants — but no body composition data has been published from any phase 3 retatrutide trial, so how much of that loss is lean tissue is currently unknown.
Should I worry about bone loss too?
It deserves more attention than it gets. Studies have found significant declines in bone mineral density at the spine, femoral neck, and total hip during GLP-1-associated weight loss, with hip loss correlating to the amount of weight lost. This matters most in older adults and anyone with existing osteopenia or osteoporosis, and it’s another reason resistance training — which loads bone as well as muscle — belongs in every plan.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. Body composition exploratory analysis, J Endocr Soc. 2021;5(Suppl 1):A16.
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. doi:10.1111/dom.16275
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial. Lancet Diabetes Endocrinol. 2025. doi:10.1016/S2213-8587(25)00092-0
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Press release, May 21, 2026.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4, NCT05931367). Press release, December 11, 2025.
- Neeland IJ, et al. Changes in lean body mass with GLP-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. doi:10.1111/dom.15728
- Jensterle M, et al. Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass. Diabetes Obes Metab. 2026. doi:10.1111/dom.70649
- Langer HT, et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function. Cell Reports Medicine. 2026.
- Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE). Nature Medicine. 2026.
- Regeneron Pharmaceuticals. Phase 2 COURAGE trial 26-week results, presented at EASD, September 2025.
- Liu Y, Walzer D, Schmitz S, et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. J Clin Endocrinol Metab. 2026;111(7):1959–1966.
- SEMALEAN study: Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity. 2025.
- Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. 2025.
- Kohan J, et al. High-Intensity Focused Electromagnetic (HIFEM) Energy With and Without Radiofrequency for Noninvasive Body Contouring: A Systematic Review. Aesthetic Plast Surg. 2024;48(6):1156–1165.
This article is for general educational purposes and is not a substitute for individualized medical advice. Treatment decisions regarding weight management medications should be made with a qualified physician who knows your medical history. Results vary between individuals.
Off-label use: Ozempic® (semaglutide) is FDA-approved for type 2 diabetes; its use for weight loss is off-label. Mounjaro® (tirzepatide) is FDA-approved for type 2 diabetes; its use for weight loss is off-label. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved for chronic weight management. Retatrutide is investigational and is not FDA-approved for any indication.
Trademarks: Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Emsculpt NEO® is a registered trademark of BTL. Sanjiva Medical Spa is not affiliated with, endorsed by, or sponsored by any of these companies. These names are used here for identification and educational purposes only.
Reviewed and authored by Dr. Praveen Guntipalli, MD, FACP — Board-Certified in Internal Medicine and Obesity Medicine, Medical Director of Sanjiva Medical Spa, Dallas, TX. Sanjiva Medical Spa · 5633 W Lovers Lane, Dallas, TX 75209 · 469.336.6769
Lose Fat. Preserve Muscle. Improve Health.
Sanjiva’s physician-led weight-management approach focuses on body composition, protein, resistance training, individualized dose progression, tracking and long-term maintenance.
Book Your Consultation